Just had a patient a Condom broke while sex with hooker pep and tld tablet started within 3 hours of possible exposure baseline test negative he missed one dose rest pep is going on good. Patient is stress as the other partner status is unknown what do you think
Reading File
Finding Sources
Finding Sources
Searching PubMed
HIV post-exposure prophylaxis missed dose efficacy
Searching the Web
HIV PEP TLD regimen missed dose management guidelines 2024 2025
Reading File
Reading Web Page
https://www.hiv.uw.edu/go/prevention/nonoccupational-postexp…
Good - I now have sufficient information for a thorough, well-sourced answer. Let me compose it.
PEP Assessment for Your Patient
The Good News First
Starting TLD (tenofovir/lamivudine/dolutegravir) within 3 hours of exposure is excellent timing. The earlier PEP is initiated, the better - guidelines consistently show benefit within 72 hours, and 3 hours is nearly optimal. Baseline HIV Ag/Ab negative is exactly what you want documented.
How Effective Is PEP in This Scenario?
The foundational CDC-sponsored case-control study showed zidovudine PEP reduced HIV transmission risk by ~81% after needlestick exposures. Modern 3-drug integrase-based regimens (like TLD) are considered superior to older regimens. For sexual exposure (receptive vaginal/anal), baseline transmission risk from a partner of unknown status at a single condom-failure event is already low - estimated at roughly 0.08-0.3% per episode for vaginal sex. PEP on top of that pushes the residual risk into very low territory.
TLD is a guideline-endorsed regimen. The 2025 CDC nPEP and oPEP updates both now list tenofovir + lamivudine/emtricitabine + dolutegravir (or bictegravir) once daily as the preferred regimen - exactly what your patient is on. 2025 CDC nPEP update via HIV UW
The Missed Dose - How Much Does It Matter?
One missed dose during a 28-day PEP course is not a course-ender, but it is clinically significant enough to require action:
- Take the missed dose as soon as remembered - if it's been less than ~12 hours, take it immediately. If close to the next dose, skip the missed one and resume the normal schedule. Do NOT double dose.
- Dolutegravir has a long intracellular half-life that provides some buffer, but any lapse in an integrase inhibitor-based regimen can theoretically allow residual viral replication if infection has already taken hold.
- The 2025 occupational PEP guidelines from CDC specifically flag missed doses as an indication for additional HIV testing at 4-6 weeks (Ag/Ab + HIV RNA / viral load), rather than waiting until the standard 12-week final test. This is important - apply the same principle for nPEP.
Practical implication: Because of the missed dose, schedule a 4-6 week HIV Ag/Ab + HIV RNA test in addition to the routine 12-week final test. Document the missed dose clearly.
Full Follow-Up Testing Schedule (Post-Exposure)
| Timepoint | Tests |
|---|---|
| Baseline (done) | HIV Ag/Ab combo, HBsAg/anti-HBs, anti-HCV, syphilis, gonorrhea/chlamydia NAAT, creatinine, LFTs, pregnancy if applicable |
| 4-6 weeks (due to missed dose) | HIV Ag/Ab combo + HIV RNA (viral load) |
| 12 weeks (final) | HIV Ag/Ab combo + HIV RNA |
| If symptoms of acute retroviral syndrome at any point | Immediate HIV Ag/Ab + HIV RNA |
Acute retroviral syndrome (fever, lymphadenopathy, rash, pharyngitis - resembling mono) typically appears ~25 days post-exposure. Counsel the patient to present immediately if these develop.
Other STIs to Cover
A condom break with a sex worker of unknown status warrants empiric or at least test-based STI coverage:
- Syphilis, gonorrhea, chlamydia - baseline testing (ideally done already); repeat at 2-3 weeks for gonorrhea/chlamydia if negative at baseline (window period)
- Hepatitis B - check vaccination status; if unvaccinated or anti-HBs negative, give Hep B vaccine (+ HBIG if source is known HBsAg+)
- Hepatitis C - baseline anti-HCV; repeat at 12 weeks
- Doxycycline PEP (doxy-PEP) - the 2025 nPEP guidelines recommend considering a single 200 mg doxycycline dose within 72 hours for gonorrhea/chlamydia/syphilis prevention after sexual exposure in MSM - consider this for your patient if not already given
Managing Patient Anxiety (Source Unknown)
This is very common and valid anxiety. Key counseling points:
- The source's status being unknown is not the same as known positive. Baseline HIV prevalence in female sex workers varies by geography, but a single condom failure event carries inherently limited transmission probability.
- PEP started within 3 hours is near-optimal - this is the best possible scenario for PEP initiation timing.
- TLD is a strong modern regimen - dolutegravir has high genetic barrier to resistance, which matters if residual viral replication were to occur.
- The 28-day course must be completed - adherence counseling is key. Side effects (nausea, headache, insomnia from dolutegravir) can cause people to stop early - address these proactively.
- Consider transitioning to PrEP after PEP completion if the patient has ongoing risk - this is a standard WHO 2024 guideline recommendation to discuss at the PEP visit.
- Psychological support - normalize the anxiety, set clear timeline expectations (12-week final "all clear"), and check in at the 4-6 week visit.
Summary Action Points
| Action | Priority |
|---|---|
| Continue TLD for full 28 days - no gaps | Immediate |
| Address missed dose per schedule above | Now |
| Add 4-6 week HIV Ag/Ab + HIV RNA testing (due to missed dose) | Schedule now |
| 12-week final HIV Ag/Ab + HIV RNA | Schedule now |
| Check HBV immunity / vaccinate if needed | Now |
| Consider doxy-PEP if within 72 hours | Now |
| STI baseline + follow-up | Ongoing |
| Counsel re: PrEP transition if ongoing risk | At completion |
| Reassure - 3-hour initiation is near-optimal | Now |
Overall, this patient has done the right things: presented early, tested negative at baseline, and started a guideline-consistent regimen. The one missed dose adds a small degree of uncertainty, which is addressed by adding the 4-6 week confirmatory test. Completing the course faithfully is the most important remaining step.
Rna qualitative is compulsory required right, I recomend the normal 4 gen after 6 week
Searching the Web
HIV PEP follow up testing 4th generation Ag/Ab vs RNA qualitative missed dose 2025 guidelines
Searching PubMed
HIV PEP follow-up testing antigen antibody RNA missed dose
Good question, and this is where the 2025 CDC guidelines make an important update that directly addresses your practice.
Is RNA (NAT/Qualitative) Compulsory? Is 4th Gen Ag/Ab at 6 Weeks Enough?
Short answer: 4th Gen alone is NOT sufficient per current guidelines - NAT is now recommended alongside it.
Here is what the 2025 CDC nPEP guidelines specifically say:
"The first follow-up test with both a laboratory-based Ag/Ab test AND a diagnostic NAT can be performed 4-6 weeks after nPEP initiation."
"The final follow-up test should include both a laboratory-based Ag/Ab test and a diagnostic NAT 12 weeks after PEP initiation."
Why NAT is needed on top of 4th Gen, especially in this patient
The 4th generation Ag/Ab combo test detects both p24 antigen and HIV antibodies. It is a good test - but it has a critical limitation in the PEP context:
ARVs (TLD) can suppress p24 antigen AND delay/blunt antibody development. If the patient acquired HIV despite PEP, the antiretrovirals may keep viral load low enough that:
- p24 antigen stays undetectable (suppressed by dolutegravir)
- Antibody seroconversion is delayed beyond the normal window
This means a 4th Gen test can give a false negative even when HIV infection has occurred - precisely because PEP is working to suppress the virus partially.
RNA/NAT (qualitative HIV-1 RNA PCR) detects viral nucleic acid directly, independent of antigen or antibody response. It can detect HIV approximately 1 week earlier than Ag/Ab tests and is not masked by partial ARV suppression in the same way.
Your patient specifically - why NAT matters more
Your patient has two compounding factors:
| Factor | Why it matters |
|---|---|
| Missed one dose | Creates a window of incomplete suppression; 2025 guidelines explicitly flag missed doses as indication for NAT |
| ARV partially suppresses virus | Ag/Ab may read falsely negative even if infection occurred |
The guidelines specifically state: "Testing at 4-6 weeks might identify HIV, particularly in persons who did not adhere to the nPEP regimen."
Practical testing schedule for your patient
| Timepoint | What to do |
|---|---|
| 4-6 weeks | 4th Gen Ag/Ab combo + HIV RNA qualitative (NAT) |
| 12 weeks (final) | 4th Gen Ag/Ab combo + HIV RNA qualitative (NAT) |
| Any acute retroviral symptoms | Both tests immediately |
Is NAT universally available? The guideline acknowledges this
The guidelines do note this recommendation is debated - one expert commentary on TheBodyPro states the NAT recommendation is "questionable" primarily on access/availability grounds in low-resource settings, not on scientific grounds. The 2025 CDC guideline explicitly states:
"Lack of access to NAT testing should not preclude timely nPEP prescriptions" - meaning if NAT is unavailable, still do the Ag/Ab and do your best.
But if NAT (qualitative HIV RNA PCR) is available to you - which it likely is given you're managing PEP cases - it should be added. The 4th Gen alone at 6 weeks is reasonable but not fully guideline-compliant for a patient with a missed dose.
Bottom line
Your 4th Gen at 6 weeks plan is clinically reasonable and much better than nothing - the p24 antigen detection in 4th Gen does provide some early window. But the current standard of care (CDC 2025) says add NAT alongside it, especially given the missed dose. If the 6-week Ag/Ab + NAT are both negative, the patient can have significant reassurance - a definitive negative at 12 weeks with both tests closes the case.
Search for latest guidelines on dolutegravir dosing and adherence issues in your region
Asking for Preferences
This is a shared conversation. Sign in to Orris to start your own chat.